Abstract：
People with cystic fibrosis (pwCF) have an altered gastrointestinal microbiome. These individuals also demonstrate propensity toward developing small intestinal bacterial overgrowth (SIBO). The dysbiosis present has intestinal and extraintestinal implications, including potential links with the higher rates of gastrointestinal malignancies described in CF. Given these implications, there is growing interest in therapeutic options for microbiome modulation. Alternative therapies, including probiotics and prebiotics, and current CF transmembrane conductance regulator gene modulators are promising interventions for ameliorating gut microbiome dysfunction in pwCF. This article will characterize and discuss the current state of knowledge and expert opinions on gut dysbiosis and SIBO in the context of CF, before reviewing the current evidence supporting gut microbial modulating therapies in CF.
摘要：
患有囊性纤维化(pwCF)的人具有改变的胃肠道微生物组。这些个体还表现出发展小肠细菌过度生长(SIBO)的倾向。目前的生态失调具有肠道和肠道外的影响，包括与CF中描述的胃肠道恶性肿瘤发病率较高的潜在联系。鉴于这些含义，对微生物组调节的治疗选择越来越感兴趣。替代疗法,包括益生菌和益生元,和目前的CF跨膜传导调节基因调节剂是改善pwCF肠道微生物组功能障碍的有希望的干预措施。本文将在CF的背景下描述和讨论有关肠道生态失调和SIBO的知识现状和专家意见，在回顾目前支持CF肠道微生物调节疗法的证据之前。
